hackint0sh/New-Dataset huggingface dataset:
Changes in FI status were also associated with improvements in other areas of functioning. NE+MD participants experienced reductions in depression symptomatology, with Beck Depression Inventory scores lower than intake at Weeks 4 and 8 (p's\<.05) and no changes among NE participants. NE+MD participants also experienced improvements on four of the eight subscales of the RAND-36 Quality of Life Health Survey (i.e., General Health, Bodily Pain, Mental Health, Role Emotional; p's\<.05), with no changes among NE participants.
This study represents the first effort to develop and evaluate a novel intervention to reduce FI and related problems among individuals with OUD. These pilot data support the feasibility, acceptability and initial efficacy of the NE+MD intervention for improving household FI, as well as provide exciting new preliminary evidence suggesting that FI may be linked to participants' mental and physical health. conditions: Food Security studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, parallel-groups pilot study primaryPurpose: TREATMENT masking: NONE count: 50 type: ACTUAL name: NE + Meal Delivery (NE+MD) intervention measure: Household food insecurity Survey sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Vermont city: Burlington state: Vermont zip: 05401 country: United States lat: 44.47588 lon: -73.21207 hasResults: False
nctId: NCT06374290 id: HSC-MS-24-0024 briefTitle: Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-02-15 date: 2025-04-15 date: 2024-04-18 date: 2024-04-18 name: The University of Texas Health Science Center, Houston class: OTHER briefSummary: The purpose of this study is to assess the feasibility and safety of injectable naltrexone (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate change on smoking-related measures and symptoms of schizophrenia. conditions: Smoking Cessation studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 20 type: ESTIMATED name: Naltrexone (Vivitrol) name: Bupropion measure: Feasibility as assessed by the percentage of participants that enroll in the study measure: Percentage of participants that complete 3 weeks of treatment measure: Safety as assessed by the percentage of participants that show no serious adverse events measure: Change in number of cigarettes smoked per day (CPD) measure: Change in smoking urges as assessed by the Questionnaire on Smoking Urges (QSU) measure: Reduction in number of cigarettes consumed when price is at 0 as assessed by the Cigarette Purchasing Task (CPT) measure: Change in psychiatric symptoms as assessed by the score on the Brief Psychiatric Rating Scale (BPRS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The University of Texas health Science Center at Houston city: Houston state: Texas zip: 77030 country: United States name: Jin H Yoon, PhD role: CONTACT phone: 713-486-2800 email: jin.ho.yoon@uth.tmc.edu name: Jessica Vincent role: CONTACT phone: (713) 486-2645 email: Jessica.N.Vincent@uth.tmc.edu lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06374264 id: NM100 briefTitle: Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder acronym: aNiMatO overallStatus: NOT_YET_RECRUITING date: 2024-06-15 date: 2024-12-31 date: 2024-12-31 date: 2024-04-18 date: 2024-04-24 name: MedRhythms, Inc. class: INDUSTRY name: Alexion Pharmaceuticals, Inc. briefSummary: The purpose of this proof of concept study is to assess the acceptability and safety of MR-C-014 in persons with Neuromyelitis optica spectrum disorder (NMOSD) who have a gait deficit. conditions: Neuromyelitis Optica Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: MR-C-014 measure: Participant acceptability of MR-C-014 measure: Number of device-related adverse events (AEs) measure: 6-Minute Walk Test (6MWT) measure: Number of walks per week measure: Spatiotemporal symmetry of gait as measured by the MR-C-014 sensors measure: Spatiotemporal variability of gait as measured by the MR-C-014 sensors measure: Stride length as measured by the MR-C-014 sensors measure: Falls Efficacy Scale-International (FES-I) measure: Number of falls as recorded in Falls Diary measure: Multiple Sclerosis Walking Scale (MSWS-12) measure: Visual Analogue Scale (VAS) measure: Generalized Anxiety Disorder-7 (GAD-7) measure: 9 Hole Peg Test (9-HPT) measure: Symbol Digit Modalities Test (SDMT) measure: Fatigue Scale for Motor and Cognitive Functions (FSMC) measure: Expanded Disability Status Scale (EDSS) Ambulation Score measure: Activities-Specific Balance Confidence Scale (ABC) measure: Patient Experience and Satisfaction Survey sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Massachusetts General Hospital city: Boston state: Massachusetts zip: 02114 country: United States name: Eric Klawiter, MD role: CONTACT email: EKLAWITER@mgh.harvard.edu lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06374251 id: 0S-23-2 id: NCI-2023-08890 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 0S-23-2 type: OTHER domain: USC / Norris Comprehensive Cancer Center id: P30CA014089 type: NIH link: https://reporter.nih.gov/quickSearch/P30CA014089 briefTitle: Narrative Medicine for Improving Well-Being in Patients With Gastrointestinal Cancers overallStatus: RECRUITING date: 2023-09-27 date: 2024-09-27 date: 2025-03-27 date: 2024-04-18 date: 2024-04-18 name: University of Southern California class: OTHER name: National Cancer Institute (NCI) briefSummary: This clinical trial assesses whether narrative medicine methods may improve the sense of well-being among gastrointestinal (GI) (digestive system) cancer patients. Narrative medicine is a clinical approach where providers can use a patient's own narrative (perspective) of their illness to promote healing and resilience. By applying narrative medicine's main tool, close reading, to clinical practice, clinicians learn to listen and attend to patients more deeply. This allows for freer communication and the creation of a healthcare encounter that centers on the psychological and emotional well being of the patient in addition to their medical conditions. Narrative medicine can include close reading, creative or reflective writing, and discussion. These methods may help patients with GI cancer to reflect on their life stories, both inside and outside of their illness experience, and help them gather skills to optimize their well-being. conditions: Malignant Digestive System Neoplasm studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 10 type: ESTIMATED name: Discussion name: Interview name: Survey Administration measure: Number of participants who complete the narrative medicine sessions measure: Change in well-being scores sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: USC / Norris Comprehensive Cancer Center status: RECRUITING city: Los Angeles state: California zip: 90033 country: United States name: Eve L. Makoff role: CONTACT phone: 323-865-3000 email: makoff@usc.edu name: Eve L. Makoff role: PRINCIPAL_INVESTIGATOR lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06374238 id: UG3HL165839 type: NIH link: https://reporter.nih.gov/quickSearch/UG3HL165839 id: UG3HL165839 type: NIH link: https://reporter.nih.gov/quickSearch/UG3HL165839 briefTitle: Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain acronym: PRESENCE overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2027-12 date: 2028-05 date: 2024-04-18 date: 2024-04-18 name: University of Pittsburgh class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain, opioid use, and healthcare utilization among AYAs with SCD. It also seeks to understand the role of personalized peer support in enhancing engagement and outcomes of digital CBT interventions.
By leveraging existing infrastructure for delivering virtual peer support interventions, tailored digital CBT programs for individuals with SCD, and partnerships with CBOs, the study aims to provide valuable insights into the feasibility and effectiveness of digital CBT as a pain management strategy for this vulnerable population. conditions: Pain conditions: Sickle Cell Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Three-arm, phase III randomized controlled effectiveness trial. Participants will be randomized 3:3:2 into (1) CBT + peer, (2) self-guided CBT, or (3) UC, stratified by site primaryPurpose: TREATMENT masking: NONE count: 470 type: ESTIMATED name: CBT+ Health coach name: CBT w/o Health Coach ( self-guided) name: Usual Care measure: Determine the effectiveness of any digital CBT (CBT + peer or self-guided CBT) vs usual care (UC) to improve pain intensity for AYAs with SCD and chronic pain measure: Determine the effectiveness of any digital CBT (CBT + peer or self-guided CBT) vs usual care (UC) to improve pain interference for AYAs with SCD and chronic pain measure: Determine the effectiveness of CBT+ peer vs. self-guided CBT to improve pain intensity for AYAs with SCD and chronic pain measure: Determine the effectiveness of CBT+ peer vs. self-guided CBT to improve pain interference for AYAs with SCD and chronic pain measure: Determine the sustained effectiveness of any digital CBT (CBT + peer or self-guided CBT) vs UC to improve pain intensity for AYAs with SCD and chronic pain measure: Determine the sustained effectiveness of any digital CBT (CBT + peer or self-guided CBT) vs UC to improve pain interference for AYAs with SCD and chronic pain measure: Determine the sustained effectiveness of CBT+ peer vs self-guided CBT to improve pain intensity of AYAs with SCD and chronic pain measure: Determine the sustained effectiveness of CBT+ peer vs self-guided CBT to improve pain interferences of AYAs with SCD and chronic pain sex: ALL minimumAge: 16 Years maximumAge: 30 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06374225 id: 23-0866 briefTitle: Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention acronym: SAVE-O2 AI overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-12-31 date: 2026-05-01 date: 2024-04-18 date: 2024-04-18 name: University of Colorado, Denver class: OTHER name: United States Department of Defense name: O2matic ApS name: IDTS Medical, Inc. briefSummary: This study is a multicenter randomized controlled trial to determine the effectiveness of a closed loop/autonomous oxygen titration system (O2matic PRO100) to maintain normoxemia (goal range SpO2 90-96%, target 93%) during the first 72 hours of acute injury or illness, compared to standard provider-driven methods (manual titration with SpO2 target of 90-96%). conditions: Critical Illness conditions: Wounds and Injury conditions: Disease Attributes conditions: Pathologic Processes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 300 type: ESTIMATED name: Automated Titration (O2matic) measure: Proportion of time spent within the targeted normoxemia range measure: Amount of supplemental oxygen administered measure: Proportion of time spent in hypoxemia (SpO2<88%) measure: Proportion of time spent in hyperoxemia (SpO2 >96%) measure: Time to Room Air sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Colorado city: Aurora state: Colorado zip: 80045 country: United States lat: 39.72943 lon: -104.83192 facility: Oregon Health and Sciences University city: Portland state: Oregon zip: 97239 country: United States lat: 45.52345 lon: -122.67621 facility: Vanderbilt University Medical Center city: Nashville state: Tennessee zip: 37232 country: United States lat: 36.16589 lon: -86.78444 hasResults: False
nctId: NCT06374212 id: 24-0191 briefTitle: Anifrolumab for Hidradenitis Suppurativa overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-12 date: 2024-04-18 date: 2024-04-18 name: University of North Carolina, Chapel Hill class: OTHER name: AstraZeneca briefSummary: This clinical trial aims to study if a drug called anifrolumab works to treat Hidradenitis Suppurativa (HS) as well as its effect in quality of life before and after treatment. Anifrolumab is a monoclonal antibody that inhibits several processes that have been shown to be involved in the development of HS.
* Stay 20 minutes after the infusion for monitoring conditions: Hidradenitis Suppurativa conditions: Acne Inversa conditions: Hidradenitis studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: All study participants, if eligible, will receive the study drug (anifrolumab). primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Anifrolumab measure: Percentage of participants achieving at least a Hidradenitis Suppurativa Clinical Response score of 50 (HiSCR 50) at 12 weeks measure: Percentage of participants achieving a HiSCR 50 at 24 weeks measure: Percentage of participants who achieve a Hidradenitis Suppurativa Clinical Response score of 75 (HiSCR 75) at 12 weeks measure: Percentage of participants who achieve a HiSCR 75 at 24 weeks of treatment. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UNC Dermatology and Skin Cancer Center city: Chapel Hill state: North Carolina zip: 27516 country: United States name: Erika Hanami role: CONTACT phone: 984-974-3682 email: erika_hanami@med.unc.edu name: Christopher Sayed, MD role: PRINCIPAL_INVESTIGATOR lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06374199 id: 24-0181 briefTitle: Med-South Lifestyle Program for Pregnancy overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-01 date: 2025-01 date: 2024-04-18 date: 2024-04-18 name: University of North Carolina, Chapel Hill class: OTHER briefSummary: Eating a Mediterranean-style diet during pregnancy improves pregnancy outcomes, yet most Americans who are pregnant do not follow this type of dietary pattern. There is increasing interest in Food is Medicine programs, which provides foods to patients to improve health outcomes - food provided in this context is called medically tailored meals. The research team at the UNC Center for Health Promotion and Disease Prevention is developing a Food is Medicine program to improve pregnancy outcomes and at this point the team is ready to test the program.
The purpose of this study is to assess the feasibility and acceptability of a Food is Medicine intervention when started during the first trimester of pregnancy. The eating pattern to be evaluated in this study is a Mediterranean-style dietary pattern adapted for the southern United States - thus, the program is called "Med-South." All who take part will receive Med-South dietary counseling. In addition, to help participants follow a Med-style dietary pattern, one group of study participants will receive extra virgin olive oil and nuts. The other group will receive extra virgin olive oil, nuts, and frozen meals (medically tailored meals) that align with the Med-South dietary pattern. Participants will be assigned at random (like flipping a coin) to one of these groups conditions: Pregnancy Complications studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Standard 2 group parallel randomized trial study design. primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Med-South Lifestyle Intervention for Pregnancy--Arm 1 name: Med-South Lifestyle Intervention for Pregnancy--Arm 2 measure: Percent that would recommend this program to others who are pregnancy measure: Percent of participants who take part in the 10 study counseling sessions measure: Maternal diet quality measure: skin carotenoids sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Center for Health Promotion and Disease Prevention/UNC-Chapel Hill city: Chapel Hill state: North Carolina zip: 27599 country: United States lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06374186 id: 2095072 id: 2095072 type: OTHER domain: UMKC IRB briefTitle: Continuous Glucose Monitoring, Contingency Management, and Motivational Interviewing for Patients With Type 2 Diabetes in Kansas City acronym: COMMITTED2-KC overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-31 date: 2025-04-08 date: 2024-04-18 date: 2024-04-18 name: University of Missouri, Kansas City class: OTHER briefSummary: This study is evaluating a behavioral treatment program that uses diabetes coaching and financial rewards in addition to continuous glucose monitoring to improve diabetes management in adult patients with type 2 diabetes. This study will evaluate if this behavioral treatment program increases individual adherence to a diabetes treatment plan and improves blood sugar management. conditions: Type 2 Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A randomized parallel-group pilot study of a combination intervention using Motivational Interviewing (MI) and Contingency Management (CM) for patients with T2DM. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Because this is a behavioral intervention, participant blinding is not possible. Randomization will occur after baseline assessment and participants will be instructed to not tell their provider their assigned condition. whoMasked: CARE_PROVIDER count: 40 type: ESTIMATED name: Behavioral Intervention with financial rewards and coaching name: Control measure: Time in target blood glucose range per CGM measure: Hemoglobin A1C measure: Diabetes Quality of Life Brief Inventory measure: Diabetes Distress Scale measure: PROMIS Medication Adherence Scale measure: Perceived Dietary Adherence Questionnaire measure: Motivation and Confidence Ruler sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Missouri - Kansas City School of Medicine city: Kansas City state: Missouri zip: 64108 country: United States name: Carrie R Kriz role: CONTACT phone: 816-512-7473 email: mckinleycr@umkc.edu name: Jared M Bruce, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.09973 lon: -94.57857 hasResults: False
nctId: NCT06374173 id: TGI6-T1-01 briefTitle: A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors overallStatus: RECRUITING date: 2024-01-03 date: 2027-09 date: 2027-12 date: 2024-04-18 date: 2024-04-18 name: Hefei TG ImmunoPharma Co., Ltd. class: OTHER briefSummary: A Phase 1 Study to Evaluate TGI-6 in Subjects with Locally Advanced/Metastatic Solid Tumors conditions: Advanced or Metastatic Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 123 type: ESTIMATED name: TGI-6 Injection measure: Dose-limiting Toxicity (DLT) measure: Dose-Finding measure: Frequency and Severity of Adverse Events (AE) measure: Pharmacokinetics of TGI-6 measure: Pharmacokinetics of TGI-6 measure: Number of subjects with Anti-TGI-6 antibody positive measure: Objective Response Rate (ORR) measure: Duration of Response (DoR) measure: Disease Control Rate (DCR) measure: Progression Free Survival (PFS) measure: Overall Survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital status: RECRUITING city: Beijing country: China name: Hang Zhou role: CONTACT email: hang.zhou@tgimmunopharma.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06374160 id: 70115371 briefTitle: Exercise in Patients With Advanced Non-small Cell Lung Cancer acronym: BREATH overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-04-30 date: 2026-08-31 date: 2024-04-18 date: 2024-04-18 name: University Hospital, Essen class: OTHER name: German Cancer Aid briefSummary: Lung cancer is one of the most common types of cancer in Germany, with 56,839 new cases and 45,072 deaths annually. Approximately 70% of patients with non-small cell lung cancer (NSCLC) are diagnosed at an advanced stage and suffer from comorbidities and symptoms such as fatigue, tiredness, and loss of strength. The standard first-line treatment for metastatic NSCLC includes platinum-based chemoimmunotherapy followed by immunotherapy maintenance. Exercise can have positive effects on symptoms such as shortness of breath, fatigue, quality of life, and physical fitness. However, there is a lack of current scientific evidence for the effectiveness of exercise in advanced lung cancer patients. No current trial investigated exercise in advanced NSCLC receiving immunotherapy so far.
The BREATH-study is a prospective 3-arm randomized controlled trial (RCT). In total, the investigators plan to recruit 104 patients. A 2:1:1 randomization will be performed with three study groups: a control group and two exercise therapy groups (strength+endurance exercise/only endurance exercise). One group receives individual endurance training and the other group a combination of individual endurance and strength training. Both treatment groups will be treated twice a week for 12 weeks. The control group will initially receive standard treatment without exercise for 12 weeks and will then be randomized into one of the other two study groups with exercise twice a week for 12 weeks. This approach allows for a sufficiently large sample for comparisons between exercise therapy and the control group, as well as between the two exercise therapy approaches.